We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $1.88 · 4 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
DocGo Launches Mobile Phlebotomy Services in South Florida - geneonline.com
DocGo Launches Mobile Phlebotomy Services in South Florida geneonline.com
DocGo launches mobile phlebotomy services in southern Florida - Investing.com UK
DocGo launches mobile phlebotomy services in southern Florida Investing.com UK
At-home blood draws come to South Florida as DocGo expands - Stock Titan
At-home blood draws come to South Florida as DocGo expands Stock Titan
DocGo Launches Mobile Phlebotomy Services in South Florida
DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference
DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.15 | — | — | $75.4M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.09 | — | — | $96.03M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.22 | — | — | $495.72M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.17 | — | — | $357.04M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 25. | Canaccord Genuity | — | Maintain | Hold → Hold | — | Canaccord Genuity: Hold |
| 2026. 03. 17. | Stifel | — | Maintain | Buy → Buy | — | Stifel: Buy |
| 2026. 03. 17. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
| 2026. 03. 17. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2025. 11. 12. | Canaccord Genuity | — | Maintain | Hold → Hold | — | Canaccord Genuity: Hold |
| 2025. 08. 22. | Canaccord Genuity | — | Maintain | Hold → Hold | — | Canaccord Genuity: Hold |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.